nach oben

Erschienen in:

01.05.2019 | Short Communication

First experience of durable cytoreduction in chronic lymphoid leukemia with ¹⁷⁷Lu-DOTATATE

verfasst von: Tijana Savovic, John O. Prior, Marie Nicod-Lalonde, Alberic Bressoud, Stéphane Roux, Niklaus Schaefer, Marie Meyer

Erschienen in: Medical Oncology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

This is the first described case of effective and durable cytoreduction after PRRT with ¹⁷⁷Lu-DOTATATE in a 75-year-old female, with B cell chronic lymphoid leukemia, and well-differentiated metastatic neuroendocrine tumor.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.CrossRef

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:2416–23.CrossRef

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-DOTATATE for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125–35.CrossRef

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.CrossRef

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:2124–30.CrossRef

Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, Pöppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med Off Publ Soc Nucl Med. 2013;54:1857–61.

Ferone D, Lombardi G. Colao A [Somatostatin receptors in immune system cells]. Minerva Endocrinol. 2001;26:165–73.PubMed

Hiruma K, Koike T, Nakamura H, Sumida T, Maeda T, Tomioka H, et al. Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology. 1990;71:480–5.PubMedPubMedCentral

Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, et al. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol. 1995;13(8):2012–5.CrossRef

Titel: First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE
verfasst von: Tijana Savovic
John O. Prior
Marie Nicod-Lalonde
Alberic Bressoud
Stéphane Roux
Niklaus Schaefer
Marie Meyer
Publikationsdatum: 01.05.2019
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 5/2019
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-019-1266-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

First experience of durable cytoreduction in chronic lymphoid leukemia with ¹⁷⁷Lu-DOTATATE

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control

In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer

Neck management in head and neck squamous cell carcinomas: where do we stand?

Prospective assessment of taste impairment and nausea during radiotherapy for head and neck cancer

Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer

Interaction between phytotherapy and oral anticancer agents: prospective study and literature review

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie